You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物-B(01877.HK)攜手中科院微生物所開發新型冠狀病毒中和抗體
格隆匯 03-20 17:40

格隆匯3月20日丨君實生物-B(01877.HK)公告,公司董事會欣然宣佈,為積極應對當前疫情,響應國家號召,滿足對新型冠狀病毒中和抗體的緊急需要,憑藉自有的完整抗體商業化開發實力和基礎,結合中國科學院微生物研究所的病原免疫開發平台和已取得的冠狀病毒相關技術祕密,公司與中科院微生物所將合作開發新冠病毒抗體並相應簽署與次業務合作相關的協議。

中科院微生物所成立於1958年12月3日,其前身為中國科學院應用真菌研究所和中國科學院北京微生物研究室。基於公司獲得的資料,中科院微生物所目前已發展成為一個具有雄厚基礎、強大實力和廣泛影響的綜合性微生物學研究和微生物技術研發機構,擁有5個國家和中科院重點實驗室,亞洲最大的、近52萬號標的菌物標館和國內最大的、保藏了近6.1萬株菌的中國普通微生物菌種保藏管理中心,建有網絡信息中心、大型儀器中心和生物安全三級實驗室、SPF實驗動物房等技術支撐平台。

目前尚無有效抗體藥物被批准應用於治療新型冠狀病毒。次業務合作有利於加快新冠病毒抗體開發,若項目能成功開發並順利實現商業化,將提供應對新型冠狀病毒的抗體治療選擇,併為中國和世界疾病預防控制貢獻力量。

公司作為一家創新驅動型生物醫藥公司,通過次業務合作積極迴應國家號召,參與到面對肆虐全球的疫情的新藥研發的挑戰中。公司將致力於目前最緊迫的未被滿足的臨牀需求,承擔起醫藥企業的社會責任。在次業務合作中,公司將充分發揮自身研發能力,國際水準的生產能力,以及快速的迴應能力,用科學的手段對抗病毒,抗擊疫情。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account